Kazakhstan Medical Device Dossier Amendments: Change Filings and the 2028 Transition Window

1. Key takeaways

The medical device registration certificate of Kazakhstan carries no expiry date (Order No. 146, signed November 18, 2025), so there is no periodic renewal action, and the accuracy of the dossier depends entirely on the proactive filing of changes by the company. Changes that must be declared include: changes to the production site or address, changes of the authorized representative, additions or removals of models, specifications and configurations, revisions of label and instructions for use texts, changes to packaging specifications, changes to the sterilization method, and changes to the shelf life. What can wait is a purely administrative adjustment of information that does not affect safety, quality or effectiveness — but the judgment should be made cautiously, and when in doubt, file. Under the protocol signed December 29, 2025, the window for submitting change and dossier adjustment applications under national legislation runs until December 31, 2028.

2. Legal basis

3. Expert insights

Insight one: the absence of an expiry system shifts the regulatory focus from renewal to change. In ordinary markets, companies refresh their dossiers passively through the renewal cycle; Kazakhstan has no such mechanism. The consequence of neglecting changes is not an expired certificate but a register entry that no longer matches the physical product — and in supervision and inspection this constitutes a violation just the same, with a correction cost that is materially higher than the cost of timely filing would have been.

Insight two: a change of authorized representative is the most complex category of change. The representative’s name appears on the registration certificate and on the label and instructions for use, so the change requires a certificate amendment, an update of the packaging materials, and the cooperation of the outgoing representative. GRZAN recommends writing the cooperation duties and the exit mechanism clearly into the appointment agreement at the outset, because retrofitting cooperation after the relationship has soured is slow and expensive. Experience shows that the packaging update, not the certificate amendment, is where the timeline actually slips, so the print supplier should be briefed from day one.

Insight three: December 31, 2028 is the endpoint of the change window, and that is the reason for back-planning. Under the protocol, the window for submitting change and dossier adjustment applications under national legislation is preserved until December 31, 2028. Major changes filed after that date will have to follow the Union rules, where both the procedure and the cost rise. Substantial changes to legacy products should therefore be scheduled before that date, and the backlog of pending changes should be triaged well in advance of the deadline. A quarterly review of the register against the actual product configuration is the simplest control for catching drift early.

Insight four: a change and a re-registration are two distinct procedures and must not be mixed up. Re-registration applies to specific situations, such as devices produced in Kazakhstan under national rules, and its fee is 5 МРП; a change, by contrast, modifies an already registered dossier. The procedures, fees and evidence requirements differ, and choosing the wrong one leads to the application being returned, losing weeks and sometimes a quarter of market time.

Insight five: the evidence requirements of a change derive from the same source as first registration. A new production site requires QMS evidence for that site; a new model requires technical documentation and test reports; a label revision requires bilingual texts. Preparing a change as a simplified version of a first registration produces the highest pass rate, because it satisfies the reviewer’s instinct to verify the modified configuration to the same depth as the original one. Companies that keep a reusable evidence template per change category close most filings within a single round.

4. Practical recommendations

1. Build a change trigger list, assigning each trigger a responsible role and a filing deadline.
2. When the authorized representative changes, plan the certificate amendment and the packaging update together and obtain written cooperation from the outgoing representative.
3. Schedule major changes of legacy products before December 31, 2028 wherever possible.
4. Distinguish correctly between the change and re-registration procedures and prepare materials and fees to match.
5. Prepare change materials to the standard of a simplified first registration: QMS evidence for new sites, technical documentation and test reports for new models, bilingual texts for label revisions.

5. Verification checklist

• □ A change trigger list is established, with responsible roles and filing deadlines defined
• □ Mandatory items such as production site, authorized representative, models and label texts are identified
• □ The certificate amendment and packaging update for a representative change are planned in sync
• □ Major changes of legacy products are scheduled before December 31, 2028
• □ The change and re-registration procedures are correctly distinguished, with matching materials and fees
• □ Change materials are prepared to the standard of a simplified first registration

GRZAN provides registration support in Kazakhstan for manufacturers, importers and authorized representatives, covering dossier change filings, representative transitions and post-approval maintenance. For assistance, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.